People News
Dr. Jim Esinhart
Elligo Health Research has welcomed Brandon Cormier as chief commercial officer, Jody Casey as the company’s new vice president of healthcare partnerships, and Faith Holmes as medical director.
Ergomed plc has announced its intention to appoint Dr. Jim Esinhart as a non-executive director of the company.
Antidote announces that Kathy Freeman has joined their executive management team as VP of business development.
The Society for Clinical Research Sites announced that Jennifer Burgess, executive director of communications and engagement for TransCelerate BioPharma Inc., has joined the organization’s Leadership Council.
Business News
QPS hosts 28 Taiwanese delegates at headquarters
QPS announced its plans for continued growth in Asia after hosting a 28-member delegation from Taiwan at its headquarters in Delaware.
Recognition
PPD-SNBL has been named a top-five growth business and desirable employer by Randstad Japan.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.